Since no direct TLR4 inhibitors are approved for clinical use, we evaluated the effectiveness of anti-TNF-alpha therapy, a downstream product of the TLR4 pathway, in the rat model of MPS VI. Here, TLR4 is linked to mucopolysaccharidosis type 6.